Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that Snapdragon Chemistry has completed the second phase of its 51,000 square-foot expansion in Waltham, Massachusetts.

This expansion adds an additional 12,000 square feet to Snapdragon’s active pharmaceutical ingredient (API) development and manufacturing facility, including new process research and development suites with 24 hoods, a GMP stability suite, and a fifth GMP kilo-lab, designed for multi-step, end-to-end continuous processing. The new labs feature 100 L and 60 L glass-lined steel reactors, a 10 L plug flow reactor, tangential flow filtration and nanofiltration skid, 5kW photoreactor and a GMP-qualified LabOS SCADA. The new suites will be operational in June 2023.

“The capabilities and capacity added in Waltham are designed to support the industry’s most complex chemical development needs, consistent with Snapdragon’s expertise and history,” said Tom Loewald, CEO of Cambrex.

“We are pleased to see Cambrex’s ongoing commitment to providing best-in-class API process development services, supporting the completion of this expansion following our recent acquisition,” said Matt Bio, President of Snapdragon.

Snapdragon’s new capabilities align with Cambrex’s ongoing investments in continuous flow process development and small-scale clinical and commercial manufacturing in High Point, North Carolina.